Advances in treatment of autoimmune pancreatitis

Linchuang Gandanbing Zazhi

LI Ji¹ 

[1] Department of Gastroenterology, Peking Union Medical College Hospital, Beijing 100730, China;

关键词: pancreatitis;    chronic;    autoimmune diseases;    glucocorticoids;    immunosuppressive agents;   

DOI  :  10.3969/j.issn.1001-5256.2013.07.005

来源: DOAJ

【 摘 要 】

Autoimmune pancreatitis (AIP) is a type of chronic pancreatitis characterized by an autoimmune inflammatory process. Treatment protocols for AIP are still evolving. According to the articles about AIP treatment in recent years, the indications for steroid therapy include specific clinical manifestations (jaundice, abdominal pain, etc.), markedly abnormal imaging findings, and extrapancreatic organ involvement. The initial dose of steroid (prednisone) is usually 0.6 mg·kg-1·d-1 or 30-40 mg/d; after 3 weeks to 1 month of treatment with the initial dose, the dose is decreased by 5-10 mg every 1-2 weeks until it drops to 2.5-5 mg/d; this dose is maintained for 6 months to 3 years. No consensus has been reached on the adverse effect of steroid on diabetes mellitus complicating AIP. Immunosuppressive agents should be used for the patients with disease relapses or with important extrapancreatic organs involved. Rituximab might become one of the therapies for refractory AIP. Although some patients achieved remission after surgical treatment, surgery is still not recommended as a routine treatment protocol due to the complications after surgery.

【 授权许可】

Unknown